PRKAA2 and cardiac hypertrophy: This finding was also consistent with Gélinas R's conclusion that metformin treatment of myocardial hypertrophy mainly depended on AMPKɑ2‐dependent inhibition of protein O‐GlcNAcylation, an increased protein in hypertrophy condition.103